Arkitekt Ventures

Arkitekt Ventures Research Investment Thesis Arkitekt Ventures is an early-stage healthcare venture capital firm founded by Dr. Enke Bashllari, a neuroscientist turned venture investor. The fund is dedicated to improving and advancing human health by partnering with visionary technical founders working on "the hard problems" at the intersection of science and technology. Arkitekt deliberately spans both service-heavy care delivery companies and deep frontier technology applications to medicine, reflecting a distinctive thesis that the future of care sits at the intersection of physical clinics and bleeding-edge technology. The firm has an unusually high concentration in brain and nervous-system related innovation, suggesting a distinctive neuro + AI + delivery wedge inside healthtech. This positions Arkitekt at the forefront of solving complex healthcare challenges through scientific rigor and technological innovation. Investment Strategy & Philosophy Technology Focus Areas: Arkitekt invests in frontier technology applications including: Neurotech and brain-machine interfaces Artificial intelligence and machine learning for healthcare Augmented reality and virtual reality medical applications Quantum computing applications to medicine Novel AI-driven biology platforms and biotech Healthcare delivery innovation and novel care models Founder Preference: The fund specifically backs technical founders—primarily scientists, engineers, and researchers transitioning from academia or research backgrounds into entrepreneurship. Enke Bashllari's background as a neuroscientist gives her deep credibility with this founder profile. Contrarian Position: Arkitekt positions itself as a specialist in deep science and frontier technology where most traditional VCs lack expertise. By focusing on neurotech, AI-driven biology, and AR/VR applications to medicine—areas many generalist VCs avoid—the fund identifies contrarian opportunities in underexplored healthcare verticals before they become mainstream investment categories. Investment Sectors & Technology Focus Primary Sectors: Healthcare Digital (innovative care delivery, digital health platforms) Biotech & Life Sciences (AI-driven drug discovery, novel therapeutics) Neurotech (brain-machine interfaces, neural monitoring, cognitive enhancement) AI/ML Applications to Medicine (diagnostic AI, predictive healthcare) AR/VR Medical Applications (surgical visualization, medical training) Clinical Trials and Research Infrastructure Technology Enablers: Artificial Intelligence and Machine Learning Brain-Computer Interfaces and Neural Technology AR/VR and Spatial Computing for Healthcare Biotech and Advanced Biology Stage Focus & Check Size Investment Stages: Primary: Seed stage ($1M-$5M typical) Secondary: Series A stage (follow-ons and selective new investments) Tertiary: Pre-Seed stage (selective) Check Size Range: Pre-Seed: $0.5M-$1M Seed: $2M-$5M (typical) Series A: $7M-$12M (follow-on and selective new investments) Geographic Focus Primary: United States (New York headquartered, strong East Coast biotech connections) Secondary: International (selective investments in Europe and beyond) Recent Activity & Fund Status Fund Status: Actively deploying Recent Investments (2024-2025): Olli Health (November 2025) - Series A, $10M. Home health AI platform. Handspring Health (June 2025) - Series A, $12M. Digital therapeutics in fertility. Cofertility (April 2025) - Series A, $7.25M. Fertility and family planning. Sollis Health (December 2024) - Series B, $33M (participated). Healthcare delivery. Standard Model Biomedicine (October 2025) - Biotech in drug development. Portfolio Companies (21+ investments documented): Paradromics - Brain-machine interface technology (led $7M seed, 2018) Mural Health - Clinical trial infrastructure CertifyOS - Healthcare credentialing and compliance Tia - Digital health platform Nanite - Healthcare analytics Parsley Health - Functional medicine NOVOS - Longevity and aging research HumanFirst (acquired by ICON, 2024) - Clinical trial logistics Team & Leadership Enke Bashllari, Ph.D. - Founder and Managing Director Background: Neuroscientist by training, transitioned to venture investing Education: Harvard Business School (MBA), Vagelos College of Physicians and Surgeons Recognition: Named one of Business Insider's "Top 40 Women in Early-Stage Venture Capital" (2025) Expertise: Neurotech, biotech, AI-driven healthcare, clinical innovation Founded Arkitekt in 2017 with mission to advance human health through frontier technology The firm operates as a founder-led team with direct founder relationships and hands-on support. Decision Process & Timeline Decision Structure: Solo GP model with direct decision-making authority from Enke Bashllari Due Diligence Approach: Heavy technical diligence leveraging neuroscience background Deep science validation and market assessment Founder-founder mentorship model Timeline: Estimated 2-4 weeks for early-stage decision Summary Arkitekt Ventures represents a uniquely positioned early-stage healthcare venture fund led by a world-class technical investor (Enke Bashllari, Ph.D.). The firm's combination of deep scientific credibility, focus on frontier technology applications to healthcare, hands-on founder support, and contrarian thesis (backing "hard problems" others avoid) makes them ideally suited to identify and support the next generation of healthcare innovation leaders. Their investments in neurotech, AI-driven biology, digital therapeutics, and clinical innovation demonstrate commitment to solving fundamental healthcare challenges. The fund's ability to attract co-investment from tier-1 VCs validates their thesis and deal quality.